I publish peer-reviewed papers in a variety of journals that have a focus on cancer and cytopathology.
Nakhleh R, Fitzgibbons PL, Nowak JA, Najarian RM, Keren DF, Colgan TJ, Colasacco C, Fatherlee LA. The lifecycle of an evidence-based laboratory practice guideline: origin, update, affirmation, and impact! Arch Pathol Lab Med 2018; 142: 438 – 40.
Hollingsworth J, Lau A, Tone A, Kollara A, Allen L, Colgan TJ, Dube V, Rosen B, Murphy KJ, Greenblatt EM, Feigenberg T, Virtanen C, Brown TJ. BRCA1 mutation status and follicular fluid exposure alters NFkB signaling and ISGylation in human fallopian tube epithelial cells. Neoplasia 2018; 20: 697 – 709.
Dickson BC, Lum A, Swanson D, Bernardini MQ, Colgan TJ, Shaw PA, Yip S, Lee CH. Novel EPC1 gene fusions in endometrial stromal sarcoma. Genes Chromosomes Cancer 2018 (e-pub Aug 24).
Colgan TJ. Competing interests and HPV-based primary screening. J Obstet Gynecol Can 2017; 39: 325.
Colgan TJ. Chang MC, Nanji S, Kolomietz E. DNA genotyping of suspected partial hydatidiform moles detects clinically significant aneuploidy. Int J Gynecol Pathol 2017; 36: 217 – 221.
McCuaig J, Rosen B, Noor A, Colgan TJ, Casper R, Mitri F, Kim R. Case report: Use of tumor and germline Y chromosome analysis to guide surgical management in a 46, XX female presenting with gonadoblastoma with dysgerminoma. Int J Gynecol Pathol 2017; 36: 466 – 70.
Colgan TJ, Noor A, Nanji S, Chang MC, Kolomietz E. Molecular diagnosis of placental hydatidiform mole – innovation and outcomes. J Obstet Gynecol 2017; 39: 1049 - 52.
Colgan TJ, Chang MC, Nanji S, Kolomietz E. A re-appraisal of the incidence of placental hydatidiform mole using selective molecular genotyping. Int J Gynecol Ca 2016; 26: 1345 – 50.
Colgan TJ. Gynecologic cytology in Cancer Cytopathology – 20 years of massive change. Cancer Cytopath. 2016; 124: 535 – 7.
Colgan TJ, Geldenhuys L, Dvorakova M, Sekhon H, Auger M. Cervical screening recommendations in Canada – are they credible if policy advisors are advocates for the laboratory diagnostic industry? Can J Pathol 2016; 8 (3): 6 – 7.
Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, Assi J, Leong I, MacMillan C. Witterick I, Colgan TJ, Shukla NK, Thaka A, Sharma MC, Siu KWM, Walfish PG, and Ralhan R. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 2015; 4: e147. [Article]
Fung-Kee-Fung M, Kennedy EB, Biagi J, Colgan TJ, DiSouza D, Elit LM, Hunter A, Irish J, McLeod R, and Rosen B. An organizational guideline for gynecologic oncology services. Int. J. Gynecol. Cancer. 2015; 25: 551-8. [Article]
Fung Kee Fung M. Kennedy EB, Biagi J, Colgan TJ, D’Souza D, Elit LM, Hunter A, Irish J, McLeod R, and Rosen B. The optimal organization of gynecologic oncology services: a systematic review. Current Oncol. 2015; 22: e282–e293. [Article]
Turashvili G, Farmer P, Colgan TJ, and Childs T. Human papillomavirus-related ovarian metastasis with endocervical adenocarcinoma: Report of 2 cases and review of literature. J Low. Genital Tract Dis. 2015; 19: e60-3. [Article]
Colgan TJ, Vlasschaert M, Iakovleva G, and Kolomietz E. Egg donor pregnancy: a potential pitfall in the diagnosis of placental molar disease. Can. J. Pathol. 2015; 7: 11–14. [Article]
Kolomietz E, Maire G, Shabin N, Change M, Vlasschaert M, Dodge J, and Colgan TJ. What are the benefits and barriers to the adoption of a placental molar disease diagnostic service? Int. J. Gynecol. Pathol. 2015; 34: 411–18. [Article]
Colgan TJ, and Crafter S. The crisis in cytotechnology in Ontario: disruptive practice patterns and technology. Can. J. Pathol. 2014; 6: 68. [Article]
Chang MC, Escallon JM, and Colgan TJ. Prognostic significance of a positive axillary lymph node fine-needle aspirate in patients with invasive breast carcinoma. Cancer (Cytopath). 2014; 122 (2): 138-44. [Article]
Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, MacMillan C, Siu KWM, Walfish P, and Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int. J. Cancer. 2014; 134 (6): 1379-88. [Article]
Colgan TJ. Reply to a validation study of the Focalpoint GS imaging system for gynaecologic cytology screening. Cancer (Cytopath). 2013; 121 (12): 738. [Article]
Abdel-Mesih A, Daya D, Onuma K, Sur M, Tang S, Akhtar-Danesh N, Boutross-Tadross O, Ceballos KM, Chapman W, Colgan TJ, Deb P, Nucci M, Oliva E, and Lytwyn A. Interobserver agreement for assessing invasion in stage 1A vulvar squamous cell carcinoma. Am. J. Surg. Pathol. 2013; 37 (9): 1336-41. [Article]
Lytwyn A, Zaino R, Colgan TJ, and Otis C. Superficially invasive squamous cell carcinoma of the uterine cerivix: the assessment of key parameters. Pathology Case Reviews. 2013; 18 (4): 183-89. [Article]
Heller DS, Colgan TJ, and Allbritton J. Superficially invasive squamous cell carcinoma of the vulva and vagina. Pathology Case Reviews. 2013; 18 (4): 190-94. [Article]
Chan C, Virtanen C, Winegarden N, Colgan TJ, Brown T, and Greenblatt E. Discovery of biomarkers of endometrial receptivity through a minimally invasive approach: A validation study with implications of assisted reproduction. Fertil. Steril. 2013; 100 (3): 810-17. [Article]
Colgan TJ, Bon N, Clipsham S, Gardiner G, Sumner J, Walley V, and McLachlin CM. A validation study of the FocalPointTM GS Imaging System for gynecologic cytology screening. Cancer (Cytopath). 2013; 121 (4): 189-196. [Article]
McCluggage W, Colgan TJ, Duggan M, Hacker N, Mulvay N, Otis C, Wilkinson N, Zaino R, and Hirschowitz L. Dataset for reporting of endometrial carcinomas: recommendations from International Collaboration on Cancer Reporting (ICCR). Int. J. Gynecol. Pathol. 2013; 32: 45-65. [Article]
Kaur H, Levinsky E, and Colgan TJ. Papillary syncytial metaplasia of fallopian tube endometriosis: a potential pitfall in the diagnosis of serous tubal intraepithelial carcinoma. Arch. Pathol. Lab. Med. 2013; 137: 126-129. [Article]
Bentley J, and Working Group (incl. Colgan TJ). The Societies’ of Obstetricians and Gynecologists of Canada and the Canadian Colposcopists’ Clinical Practice Guideline: Colposcopic Management of Abnormal Cervical Cancer Screening and Histology. J. Obstet. Gynecol. Can. 2012; 34: 1188-1202.
Simmons C, Kuchuk I, Freedman O, Colgan TJ, Dodd A, Kulhanek K, Sheiner J, Dranitsaris G, Dowsett M, Folkerd E, and Clemons MJ. Are estring and vagifem equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy? Clin. Oncol. (R. Coll. Radiol.) 2012; 24: 128-29. [Article]
Darragh T, Colgan TJ, and Working Groups. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Assoicated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch. Pathol. Lab. Medicine 2012; 136: 1266-97. (J. Lower Genital Tract Dis. 2012; 16: 205-242 and Int. J. Gynecol. Pathol. 2013; 32: 76-115.) [Article]
Saslow D, and Working Groups (including Colgan TJ). American Cancer Society, American Society for Colposcopy and Cervical Pathology, & American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Am. J. Clin. Pathol.. 2012; 137: 516-42. [Article]
Colgan TJ, and Geldenhuys L. The practice of pathology in Canada: decreasing pathologist supply and uncertain outcomes. Arch. Pathol. Lab. Medicine. 2012; 136: 90-4. [Article]
Pantanowitz L, Valenstein P, Evans A, Kaplan K, Pfeifer J, Wilbur D, Collins L, and Colgan TJ. Review of the current state of whole slide imaging in pathology. J. Pathol. Inform. 2011; 2: 36-45. [Article]
Goldstein S, Neven P, Cummings S, Colgan TJ, Runowicz C, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, and Sriram U. Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes. Menopause. 2011; 18: 17-22. [Article]
Voisin S, Krakovska O, DeSouza L, Romaschin A, Colgan TJ, and Siu KWM. Identification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQ. PLoS ONE. 2011; 6: 1-11. [Article]
Nanji S, and Colgan TJ. A summary of the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines for the management of women with abnormal cervical histologic findings. Pathol. Case Reviews. 2011; 16: 67-72. [Article]
Bean S, Kurtycz D, and Colgan TJ. Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix. J. Lower Genital Tract Dis.. 2011; 15: 146-57. [Article]
Chang M, Crystal P, and Colgan TJ. The evolving role of axillary lymph node fine needle aspiration in the management of carcinoma of the breast. Cancer Cytopath. 2011; 119: 328-34. [Article]
Amir E, Freedman OC, Allen L, Colgan TJ, and Clemons M. Defining Ovarian Failure in Amenorrheic Young Breast Cancer Patients. Breast. 2010; 19: 545-8. [Article]
DeSouza L, Krakovska O, Darfler M, Krizman D, Romaschin A, Colgan TJ, and Siu K. mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. Proteomics. 2010; 10: 3108-16.[Article]
Colgan TJ. The 2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Screening Tests: Challenges Remain. Cancer Cytopathol. 2010; 118: 233-7. [Article]
Skeete D, Rittenberg P, Jong R, Murray S, and Colgan TJ. Myeloid sarcoma of the vagina: A report of two cases. J. Lower Genital Tract Dis. 2010; 14: 136-41. [Article]
Mackay H, Hirte H, Colgan TJ, Covens A, Macalpine K, Grenci P, Wang L, Mason J, Pham P, Tsao M, Pan J, Zwiebel J, and Oza A. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer. 2010; 46: 1573-79. [Article]
Hafezi-Bakhtiari S, Morava-Protzner I, Burnell M, Reardon E, and Colgan TJ. Choriocarcinoma arising in a serous carcinoma of ovary: An example of histopathology driving treatment. J. Obstet. Gynaecol. Can. 2010; 32: 698-702. [Article]
Goldstein S, Neven P, Cummings S, Colgan TJ, Runowicz C, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, and Sriram U. Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes. Menopause. 2010; 18: 1-6.[Article]
Cummings S, Ensrud K, Delmad P, Colgan TJ with the PEARL Study Team. Lasofoxifene in postmenopausal women with osteoporosis. N. Eng. J. Med. 2010; 362: 686-96. [Article]
Jaragh M, Carydis V, MacMillan C, Freeman J and Colgan TJ. Predictors of malignancy in thyroid fine needle aspirates "cyst fluid only" cases: Can potential clues of malignancy be identified? Cancer Cytopathol. 2009; 117: 305-10. [Article]
Skeete D, Riddell R, Wolfman W and Colgan TJ. Massive lymphocytic infiltration in a uterine leiomyoma post-gonadotrophin-releasing hormone agonist therapy. Can. J. Path. 2009; 1: 18-21. [Article]
DeSouza L, Romaschin A, Colgan TJ and Siu K. Absolute quantifications of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. Anal. Chem. 2009; 81: 3462-70. [Article]
Aximu D, Azad A, Ni R, Nanji S and Colgan TJ. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-a and minichromosome maintenance protein 2 expression [ProExTM C] in cervical adenocarcinoma in situ, adenocarcinoma and benign glandular mimics. Int. J. Gynecol. Pathol. 2009; 28: 114-19. [Article]
Malowany J, Rieckenberg R, Okafo B and Colgan TJ. Glomus tumor presenting as a periurethral mass. J. Lower Genital Tract Dis. 2008; 12: 316-9. [Article]
DeSouza L, Taylor A, Li W, Minkoff M, Romaschin A, Colgan TJ and Siu K. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J. Proteomic Res. 2008; 7: 3525-34. [Article]
Grin A, Colgan TJ, Laframbroise S, Shaw P and Ghazarian D. “Pagetoid” eccrine carcinoma of the vulva: Report of an unusual case with review of the literature. J. Lower Genital Tract Dis. 2008; 12: 134-9. [Article]
Davey D, Cox J, Austin R, Birdsong G, Colgan TJ, Howell LP, Husain M and Darragh TM. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J. Lower Genital Tract Dis. 2008; 12: 71-81. [Article]
Nadkarni D, Spitzer R, Kives S, Colgan TJ, Haider M and Allen L. Uterine asymmetry and dysmenorrhea in a young woman. J. Obstet. Gynaecol. Can. 2008; 30: 301-2. [Article]
Carydis V, Walker T, Wing A and Colgan TJ. Utility of p16ink4a immunocytochemistry in liquid-based cytology specimens from women treated for high grade squamous intraepithelial lesions. Acta Cytol. 2007; 51: 517-22. [Article]
Spitzer R, Wherrett D, Chitayat D, Colgan TJ, Dodge J, Joao Luiz P and Allen L. Maternal luteoma of pregnancy presenting with virilization of the female infant. J. Obstet. Gynaecol. Can. 2007; 29: 835-40. [Article]
Li H, DeSouza L, Ghanny S, Li W, Romaschin A, Colgan TJ and Siu K. Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem spectrometry. J. Proteomic Res. 2007; 6: 2615-22. [Article]
Dubé V, Grigull J, DeSouza L, Ghanny S, Colgan TJ, Romaschin A and Siu K. Verification of endometrial biomarkers previously discovered using mass-spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format. J. Proteomic Res. 2007; 6: 2648-55. [Article]
Las Heras F, Pritzker K and Colgan TJ. Chordoma arising in a mature cystic teratoma of the ovary: a case report. Pathol. Res. Pract. 2007; 203: 467-71. [Article]
Dubé V, MacDonald D, Allingham-Hawkins D, Kamel-Redi S and Colgan TJ. Vanishing Endometrial Carcinoma. Int. J. Gynecol. Pathol. 2007; 26: 271-77. [Article]
DeSouza L, Grigull J, Ghanny S, Dubé V, Romaschin A, Colgan TJ and Siu K. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics. 2007; 6: 1170-82. [Article]
Akerman M, Alves V, Bubendorf L, Colgan TJ, Itoh H, Kapila K, Katz R, Mitchell G, Mulvany N, Nasuti J, Ng W, Osamura R, Schalper J, Schmitt F, Serizawa A, Verhest A and Vielh P. How technology is reshaping the practice of nongynecologic cytology: frontiers of cytology symposium. Acta Cytol. 2007; 51: 123-50. [Article]
Renshaw A, Mody D, Walsh M, Bentz J, Colgan TJ. The significance of certification in liquid-based cytology and performance in the College of American Pathologists’ interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med. 2006; 130: 1269–72. [Article]
Renshaw A, Mody D, Wilbur D, Davey D, Colgan TJ. Letter-to-the-Editor (Reply). Arch Pathol Lab Med. 2006 Feb; 130: 144. [Article]
Renshaw A, Walsh M, Blond B, Moriarty A, Mody D, Colgan TJ. Robustness of validation criteria in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2006; 130: 1119–22. [Article]
Dubé V, Lickrish GM, MacNeill KN, Colgan TJ. Villoglandular adenocarcinoma of the hymen. J Lower Genital Tract Dis. 2006; 10: 156-60. [Article]
Renshaw A, Mody D, Styer P, Schwartz M, Ducatman B, Colgan TJ. Pap Tests with Mixed High and Low Grade Squamous Intraepithelial Lesion Features: Distinct Performance in the College of American Pathologists Interlaboratory Comparison Programme in Cervicovaginal Cytopathology. Arch Pathol Lab Med. 2006; 130: 456–9. [Article]
Renshaw A, Mody D, Wang E, Haja J, Colgan TJ. Hyperchromatic Crowded Groups in Cervical Cytology: Differing Appearances and Interpretations in Conventional and ThinPrep Preparations – A Study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2006; 130: 332–6. [Article]
Milic A, Asch MR, Hawrylyshyn PA, Allen LM, Colgan TJ, Kachura JR, Hayeems EB. Laparoscopic ultrasound guided radiofrequency ablation of uterine fibroids. Cardiovascular and Interventional Rad J. 2006; 29: 694–8. [Article]
Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oopherectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100: 58–64. [Article]
Colgan TJ. Disclosure of diagnostic errors: the death knell of retrospective pathology reviews? J. Lower Genital Tract Disease. 2005; 9: 216–8. [Article]
Guo J, Colgan TJ, DeSouza L, Rodrigues MJ, Romaschin AD, Siu KWM. Direct analysis of laser capture microdissected endometrial carcinoma and epithelium by MALDI mass spectrometry. Rapid Communications in Mass Spectrometry. 2005: 19: 2762-66. [Article]
Renshaw A, Mody DR, Wang E, Wilbur D, Colgan TJ. Measuring the significance of participant evaluation of acceptability of cases in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2005; 129: 1093-6. [Article]
Snyder TM, Renshaw AA, Styer PE, Mody DR, Colgan TJ. Altered recognition of reparative changes in ThinPrep® specimens in the College of American Pathologists Gynecologic Cytology Program. Arch Pathol Lab Med. 2005; 129: 861-5. [Article]
Renshaw A, Wang E, Mody D, Wilbur D, Davey D, Colgan TJ. Measuring the significance of field validation in the College of American Pathologist Interlaboratory Comparison Program in cervicovaginal cytology. How good are the experts? Arch Pathol Lab Med. 2005; 129: 609-13. [Article]
DeSouza L, Diehl G, Rodrigues MJ. Guo J, Romaschin AD, Colgan TJ, Siu KWM. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Research. 2005; 4: 377–86. [Article]
Guo J, Yang ECC, DeSouza L, Diehl G, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KWM. A Strategy for High-resolution and Protein Identification in Surface-Enhanced Laser Desorption / Ionization (SELDI) Mass Spectrometry: Calgranulin A and Chaperonin 10 as Protein Markers for Endometrial Carcinoma. Proteomics. 2005; 5: 1953-66. [Article]
DeSouza L, Diehl G, Yang ECC, Guo J, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KWM. Proteomic analysis of the proliferative and secretory phases of the human endometrium: Protein identification and differential protein expression. Proteomics. 2005; 5, 270-81. [Article]
Stuart G, Taylor G, Bancej C, Beaulac J, Colgan TJ, Franco E, Kropp R, Lotocki R, Mai V, McLachlin CM, Onysko J, Martin RE. Report of a 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. J Obstet Gynaecol Can. 2004; 26: 1004–14.
Colgan TJ, McLachlin CM, Cotterchio M, Howlett R, Seidenfeld AM, Mai VM. Results of the implementation of liquid-based cytology – SurePath in the Ontario screening program. Cancer (Cytopathol). 2004; 102: 362-7. [Article]
Colgan TJ. Beware of the ACG: The message about atypical glandular cells from Edmonton (editorial). J Obstet Gynaecol Can. 2004; 26: 861–2.
Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytopathology. Arch Pathol Lab Med. 2004; 128: 1224–29. [Article]
Yang ECC, Guo J, DeSouza L, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KWM. Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10. J Proteome Res. 2004; 3: 636–43. [Article]
Weinreb I, Colgan TJ. BRCA mutations and pathology in the female genital tract. Curr Diagn Pathol. 2004; 10: 326-325. [Article]
Hwang DM, Lickrish GM, Chapman W, Colgan TJ. Long-term surveillance is required for all women treated for cervical adenocarcinoma-in-situ. J Lower Gen Tract Dis. 2004; 8: 125-131. [Article]
Renshaw AA, Young NA, Birdsong GG, Styer PE, Davey D, Mody DR, Colgan TJ. Comparison of Performance of Conventional and ThinPrep® Gynecologic Preparations in the College of American Pathologists Gynecologic Cytology Program. Arch Pathol Lab Med. 2004; 128: 17-22. [Article]
Spitzer M, Wilkinson EJ, Ferris D, Waxman AG, Hatch KD, Werner C, Bibbo M, Colgan TJ, Cornelison T, Partridge EE. Management of women with cervical cytologic results interpreted as Low-Grade Squamous Intraepithelial Lesion: The foundation of the ASCCP Guidelines. J Lower Gen Tract Dis. 2003; 7: 241-9.
Renshaw AA, Davey DD, Birdsong GG, Walsh M, Styer PE, Mody DR, Colgan TJ. Precision in gynecologic cytologic interpretation: A study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2003; 127: 1413-20. [Article]
Colgan TJ. Programmatic assessments of the clinical effectiveness of gynecologic liquid- based cytology: The ayes have it. (editorial) Cancer (Cytopathol). 2003; 99: 259-62. [Article]
Weir MM, Jan E, Colgan TJ. Interinstitutional pathology consultations: a reassessment. Am J Clin Pathol. 2003; 120: 405-12. [Article]
Colgan TJ, Riddell RH, Pollett A. Costs of prophylactic resection. (letter) Can Med Assoc J. 2003; 169: 105. [Article]
Colgan TJ. Author’s reply to: Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma. (letter to editor) Int J Gynecol Pathol. 2003; 22: 315-6.
Grisaru DA, Covens A, Franssen E, Chapman W, Shaw P, Colgan TJ, Murphy J, DePetrillo D, Lickrish G, Laframboise S, Rosen B. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. Cancer. 2003; 97: 1904-8. [Article]
Colgan TJ. Challenges in the early diagnosis and staging of fallopian-tube carcinomas associated with BRCA mutations. Review article. (lead article) Int J Gynecol Pathol. 2003; 22: 109-20.
Pron G, Mocarski E, Cohen M, Colgan TJ, Bennett J, Common A, Vilos G, Kung R. Hysterectomy for complications after uterine artery embolization for leiomyoma: results of a Canadian multicenter clinical trial. J Am Assoc Gynecol Laparosc. 2003; 10: 99-106. [Article]
Colgan TJ, Pron G, Mocarski EJM, Bennett JD, Asch MR, Common A. Pathologic features of uteri and leiomyomas following uterine artery embolization for leiomyomas. Am J Surg Pathol. 2003; 27: 167-77. [Article]
Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan TJ, Puopolo M, Giardina G, Massobrio M, Diamandis EP. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. British Journal of Cancer. 2002; 87: 763-71. [Article]
Muradali D, Colgan TJ, Hayeems E, Burns P, Wilson S. Echogenic ovarian foci without shadowing: are they caused by psammomatous calcifications? Radiology. 2002; 224: 429-35. [Article]
Colgan TJ, Clarke A, Hakh N, Seidenfeld A. Screening for cervical disease in mature women: strategies for improvement. Cancer (Cytopathol). 2002; 96: 195-203. [Article]
Pitson G, Colgan TJ, Levin W, Lockwood G, Manchul L, Milosevic M, Murphy J, Fyles A. Stage II endometrial carcinoma: Prognostic factors and risk classification in 170 patients. Int J Radiation Oncology Biol Phys. 2002; 53: 862-7. [Article]
Colgan TJ, Boerner SL, Murphy J, Cole DEC, Narod S, Rosen B. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol. 2002; 85: 397-403. [Article]
Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, Colgan TJ, Chapman W, Shaw P. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol. 2002; 84: 145-9. [Article]
Grisaru D, Covens A, Chapman B, Shaw P, Colgan TJ, Murphy J, DePetrillo D, Lickrish G, Laframboise S, Rosen B. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer. 2001; 92: 2999-3004. [Article]
Colgan TJ, Murphy J, Cole DEC, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25: 1283-9. [Article]
Colgan TJ. Pap test results. Responding to Bethesda system reports. Can Fam Physician. 2001; 47: 1425-30. [Article]
Colgan TJ, Booth D, Hendler A, McCready D. Appropriate procedures for the safe handling and pathologic examination of technetium-99m-labelled specimens. Can Med Assoc J. 2001; 164: 1868-71. [Article]
Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, Colgan TJ, ET AL. Changes in the demographics and perioperative care of Stage IA2/IB1 cervical cancer over the past 16 years. Gynecol Oncol. 2001; 81: 133-7. [Article]
Colgan TJ, Austin RMA, Davey DD. The annual Papanicolaou test: women’s safety and public policy. Cancer (Cytopathol). 2001; 93: 81-5. [Article]
Case AM, Wilson S, Colgan TJ, Greenblatt EM. Fertility-sparing surgery, with subsequent pregnancy, in persistent gestational trophoblastic neoplasia: Case report and review. Human Reproduction. 2001; 16: 360-64. [Article]
Colgan TJ, Woodhouse SL, Styer PE, Kennedy M, Davey DD. Reparative Changes andthe False-Positive/False-Negative Papanicolaou Test: A Study from the CAP Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2001; 125: 134-40. [Article]
Colgan TJ, Prey MU. Significance of histiocytes and endometrial stromal cells in a postmenopausal woman who has a smear taken with a broom or brush. College of American Pathologists Today. 2000; 14: 109.
Colgan TJ. Litigation and the Canadian Pap Test: Perspectives from a single-payer system. (editorial) Diagn Cytopathol. 2000; 22: 207-10. [Article]
Colgan TJ, Davey DD. Response to question on false positive Pap smears. College of American Pathologists Today. 1999; 13: 91.
Colgan TJ, Shah R, Leyland N. Post-hysteroscopic ablation reaction: a histopathologic study of the effects of electrosurgical ablation. Int J Gynecol Pathol. 1999; 18: 325-31.
Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ, Taylor DD. AutoPap system detection of infections and benign cellular changes: results from primary screener clinical trials. Diagn Cytopathol. 1999; 21: 355-8.
Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ, Taylor DD. Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: results of a primary screening clinical trial. Cancer (Cytopathol). 1999; 87: 354-8.
Colgan TJ. Benchmarking reporting rates for cytodiagnoses. PAP Program Quarterly Review. 1999; 5: 2-3.
Weissman A, Gotlieb L, Colgan TJ, Jurisicova A, Greenblatt EM, Casper RF. Preliminary experience with subcutaneous human ovarian cortex transplantation in the NOD-SCID mouse. Biology of Reproduction. 1999; 60: 1462-7.
Bishop JW, Bigner SH, Colgan TJ, Husain M, Howell LP, McIntosh KM, Taylor DA, Sadeghi MH. Multicenter masked evaluation of AutoCyte PREP Thin layers with matched conventional smears: including initial biopsy results. Acta Cytologica. 1998; 42: 189-97.
Krieger PA, McGoogan E, Vooijs GP, Sreedevi Amma N, Cochand-Priollet B, Colgan TJ, Davey DD, Geyer JW, Goodell RM, Grohs DH, Gupta SK, Jones BA, Koss LG, Mango LJ, McCallum SM, Nielsen M, Robinowitz M, Sauer T, Schumann JL, Syrjänen KJ, Suprun HZ, Topalidis T, Wertlake PT, Whittaker J. Quality assurance/control issues: IAC Task Force Summary. Acta Cytologica. 1998; 42: 133-40.
McGoogan E, Colgan TJ, Ramzy I, Cochand-Priollet B, Davey DD, Grohs HK, Gurley AM, Husain OAN, Hutchinson ML, Knesel EA, Linder J, Mango LJ, Mitchell H, Peebles A, Reith A, Robinowitz M, Sauer T, Shida S, Solomon D, Topalidis T, Wilbur DC, Yamauchi K. Cell preparation methods and criteria for sample adequacy: IAC Task Force Summary. Acta Cytologica. 1998; 42: 25-32.
Colgan TJ. Vulvar intraepithelial neoplasia: a synopsis of recent developments. Journal of Lower Genital Tract Disease. 1998; 2: 31-6.
Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ. The AutoPap System for primary screening in cervical cytology: Comparing the results of a prospective, intended-use study with routine manual practice. Acta Cytologica. 1998; 42: 214-20.
Colgan TJ, Frable WJ. The Cytopathologist: workload, regulations, and the forgotten professional (editorial). Diagn Cytopathol. 1997; 17: 313-4.
Patten SF, Lee JSJ, Wilbur DC, Bonfiglio TA, Colgan TJ, Richart RM, Cramer H, Moinuddin S. The AutoPap 300 QC System Multicenter Clinical Trials for use in Quality Control rescreening of cervical smears: II. Prospective and archival sensitivity studies. Cancer (Cytopathol). 1997; 81: 343-7.
Patten SF, Lee JSJ, Wilbur DC, Bonfiglio TA, Colgan TJ, Richart RM, Cramer H, Moinuddin S. The AutoPap 300 QC System Multicentre clinical trials for use in Quality Control rescreening of cervical smears: I. A prospective intended use study. Cancer (Cytopathol). 1997; 81: 337-42.
Colgan TJ, Bon N, Lee JSJ, Patten SF. AutoPap 300 QC system scoring of cervical smears without “epithelial cell abnormalities”. Acta Cytol. 1997; 41: 45-9.
Colgan TJ, Smith J, Patten, SF, Lee JSJ. Enhancing the performance of the AutoPap 300 QC System with optimal staining and presentation of cervical smears. Acta Cytol. 1997; 41: 50-5.